You are being asked to take part in this study because you have triple negative (TN) breast cancer that has spread to your lymph nodes. You are also planning to get chemo-immunotherapy treatment before surgery. Radiation therapy (RT) has been shown to improve the body's immune response against tumors when it is given with a drug called pembrolizumab. The purpose of this study is to find the best and safest dose of radiation (low or high) when given with pembrolizumab. Radiation is measured in Gy (pronounced "gray"). You will be randomly assigned (like flipping a coin) to receive either a low dose RT boost (9 Gy) or a high dose RT boost (24 Gy). The RT will be given with one dose of pembrolizumab. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Are you a patient with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)? If so this could be the study for you. The purpose of this study is to investigate if the sonrotoclax in combination with obinutuzumab or rituximab works better and is safe in participants with

We're doing this study to explore how a device called TheraBionic affects people with liver cancer and their condition. This device uses special frequencies to target cancer cells and is being tested for treating advanced liver cancer.

The purpose of this immunotherapy study is to compare two different chemotherapy treatments administered before breast cancer surgery to see which has the better outcome.

Have you previously been screened for lung cancer? Or are you currently scheduled for a lung cancer screening? We are looking for Black/African American men and women between the ages of 50-80 to participate in a study about lung cancer. Compensation is provided.

Do you have a blood cancer or have received a stem cell transplant and have been diagnosed with a respiratory infection? If so, you might be eligible to take part in a study to see if an experimental treatment is effective at reducing the severity of the respiratory infection.

An important goal of this study is to evaluate the length of time cancer is not growing or spreading in participants when treated with zanzalintinib compared to everolimus. In addition, this study will also evaluate if zanzalintinib can shrink tumors and help participants live longer as compared to everolimus. This information will help researchers learn if zanzalintinib can be used to treat neuroendocrine cancer.

Do you have Acute Myeloid Leukemia (AML) and want to try a new study drug that might help treat your cancer?

Have you been diagnosed with Gastric Cancer? If so, you might be able to take part in a study to see if an investigational product is safe and effective for treating Gastric Cancer.

Have you been diagnosed with GCB Subtype of Diffuse LargeB-cell Lymphoma (DLBCL)? If so, you may be able to take part in a research study looking at Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL